{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:36:57Z","timestamp":1783730217778,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100032148","name":"Biohaven","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032148","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40122-025-00800-z","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:25:25Z","timestamp":1765445125000},"page":"325-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04408794","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mosher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-1248","authenticated-orcid":false,"given":"Robert J.","family":"Fountaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"800_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-023-01619-9","volume":"24","author":"L Fan","year":"2023","unstructured":"Fan L, Wu Y, Wei J, et al. Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain. 2023;24:79.","journal-title":"J Headache Pain"},{"key":"800_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023;19:109\u201317.","journal-title":"Nat Rev Neurol"},{"key":"800_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137.","journal-title":"J Headache Pain"},{"key":"800_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23:34.","journal-title":"J Headache Pain"},{"key":"800_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59:1286\u201399.","journal-title":"Headache"},{"key":"800_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain. 2019;20:41.","journal-title":"J Headache Pain"},{"key":"800_CR7","first-page":"197","volume":"29","author":"RE Shapiro","year":"2023","unstructured":"Shapiro RE, Martin AA, Bhardwaj S, et al. Relationships between headache frequency, disability, and disability-related unemployment among adults with migraine. J Manag Care Spec Pharm. 2023;29:197\u2013209.","journal-title":"J Manag Care Spec Pharm"},{"key":"800_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.55.5.629","volume":"55","author":"RB Lipton","year":"2000","unstructured":"Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55:629\u201335.","journal-title":"Neurology"},{"key":"800_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021;61:992\u20131003.","journal-title":"Headache"},{"key":"800_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s10194-023-01546-9","volume":"24","author":"A Hus\u00f8y","year":"2023","unstructured":"Hus\u00f8y A, Katsarava Z, Steiner TJ. The relationship between headache-attributed disability and lost productivity: 3 attack frequency is the dominating variable. J Headache Pain. 2023;24:7.","journal-title":"J Headache Pain"},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40120-020-00196-2","volume":"9","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Gupta S, Fang J, Laflamme AK, Vo P. The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther. 2020;9:535\u201349.","journal-title":"Neurol Ther"},{"key":"800_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301\u201315.","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"800_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache. 2018;58(Suppl 1):17\u201332.","journal-title":"Headache"},{"key":"800_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/head.14067","volume":"61","author":"CR Houts","year":"2021","unstructured":"Houts CR, McGinley JS, Nishida TK, et al. Systematic review of outcomes and endpoints in acute migraine clinical trials. Headache. 2021;61:263\u201375.","journal-title":"Headache"},{"key":"800_CR15","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1177\/0333102417731348","volume":"38","author":"KL Haywood","year":"2018","unstructured":"Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M. Assessing the impact of headaches and the outcomes of treatment: a systematic review of patient-reported outcome measures (PROMs). Cephalalgia. 2018;38:1374\u201386.","journal-title":"Cephalalgia"},{"key":"800_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339.","journal-title":"Headache"},{"key":"800_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17:501\u201314.","journal-title":"Nat Rev Neurol"},{"key":"800_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s10194-025-02074-4","volume":"26","author":"P Anukoolwittaya","year":"2025","unstructured":"Anukoolwittaya P, Rattanawong W, Vongvaivanich K, et al. Expert consensus on gepants for acute and preventive treatment of migraine in Thailand. J Headache Pain. 2025;26:131.","journal-title":"J Headache Pain"},{"key":"800_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s10194-025-02098-w","volume":"26","author":"LH Pan","year":"2025","unstructured":"Pan LH, Ling YH, Wang SJ, et al. Hallmarks of primary headache: part 2- tension-type headache. J Headache Pain. 2025;26:164.","journal-title":"J Headache Pain"},{"key":"800_CR20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a phase\u00a02\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62:1153\u201363.","journal-title":"Headache"},{"key":"800_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10\u00a0mg nasal spray for the acute treatment of migraine in the USA: a phase\u00a03, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22:209\u201317.","journal-title":"Lancet Neurol"},{"key":"800_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-024-01915-y","volume":"26","author":"L Powell","year":"2025","unstructured":"Powell L, O\u2019Sullivan F, Jayasinghe P, et al. Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase\u00a03 randomized controlled trial. J Headache Pain. 2025;26:1.","journal-title":"J Headache Pain"},{"key":"800_CR23","doi-asserted-by":"publisher","first-page":"333102424123294","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44:3331024241232944.","journal-title":"Cephalalgia"},{"key":"800_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s10194-025-02091-3","volume":"26","author":"Q Song","year":"2025","unstructured":"Song Q, Gao S, Tan Y. Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system. J Headache Pain. 2025;26:147.","journal-title":"J Headache Pain"},{"key":"800_CR25","doi-asserted-by":"publisher","first-page":"333102424125945","DOI":"10.1177\/03331024241259456","volume":"44","author":"K Mullin","year":"2024","unstructured":"Mullin K, Croop R, Mosher L, Fullerton T, Madonia J, Lipton RB. Long-term safety of zavegepant nasal spray for the acute treatment of migraine: a phase\u00a02\/3 open-label study. Cephalalgia. 2024;44:3331024241259456. https:\/\/doi.org\/10.1177\/03331024241259456.","journal-title":"Cephalalgia"},{"key":"800_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"800_CR27","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20\u20138.","journal-title":"Neurology"},{"key":"800_CR28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41:854\u201361.","journal-title":"Headache"},{"key":"800_CR29","doi-asserted-by":"publisher","first-page":"333102424126107","DOI":"10.1177\/03331024241261077","volume":"44","author":"R Ruscheweyh","year":"2024","unstructured":"Ruscheweyh R, F\u00f6rderreuther S, Freilinger T, et al. Minimal important difference of the Migraine Disability Assessment (MIDAS): longitudinal data from the DMKG Headache Registry. Cephalalgia. 2024;44:3331024241261077.","journal-title":"Cephalalgia"},{"key":"800_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s10194-021-01339-y","volume":"22","author":"GF Carvalho","year":"2021","unstructured":"Carvalho GF, Luedtke K, Braun T. Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire. J Headache Pain. 2021;22:126.","journal-title":"J Headache Pain"},{"key":"800_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","volume":"40","author":"BC Martin","year":"2000","unstructured":"Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache. 2000;40:204\u201315.","journal-title":"Headache"},{"key":"800_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1468-2982.2009.01852.x","volume":"29","author":"JC Cole","year":"2009","unstructured":"Cole JC, Lin P, Rupnow MF. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1. Cephalalgia. 2009;29:1180\u20137.","journal-title":"Cephalalgia"},{"key":"800_CR33","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1177\/0333102418789072","volume":"38","author":"DC Buse","year":"2018","unstructured":"Buse DC, Lipton RB, Hallstr\u00f6m Y, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018;38:1622\u201331.","journal-title":"Cephalalgia"},{"key":"800_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142\u20139.","journal-title":"N Engl J Med"},{"key":"800_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase\u00a02\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51\u201360.","journal-title":"Lancet"},{"key":"800_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-025-01984-7","volume":"26","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Tang Y, Li L, et al. The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature. J Headache Pain. 2025;26:48.","journal-title":"J Headache Pain"},{"key":"800_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/head.14128","volume":"61","author":"E Popoff","year":"2021","unstructured":"Popoff E, Johnston K, Croop R, et al. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine. Headache. 2021;61:906\u201315.","journal-title":"Headache"},{"key":"800_CR38","doi-asserted-by":"publisher","first-page":"333102423119029","DOI":"10.1177\/03331024231190296","volume":"51","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Halker Singh RB, Mechtler L, et al. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial. Cephalalgia. 2023;51:3331024231190296.","journal-title":"Cephalalgia"},{"key":"800_CR39","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1212\/WNL.0000000000201568","volume":"100","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al. Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, phase\u00a03 ADVANCE trial. Neurology. 2023;100:e764\u201377.","journal-title":"Neurology"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-025-00800-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:24:55Z","timestamp":1768404295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-025-00800-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1007\/s40122-025-00800-z","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Richard B Lipton receives research support from the NIH and the FDA. He receives research grants or consulting fees from AbbVie, Amgen, Axsome, Biohaven Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Teva, and Vedanta. He receives royalties from\n                      Wolff\u2019s Headache\n                      (8th Edition, Oxford University Press, 2009) and Informa. He holds stock\/options in Biohaven Pharmaceuticals, CoolTech, Manistee, and NuVieBio. Linda Mosher was an employee of Biohaven Pharmaceuticals, owns stock in Biohaven Ltd, is an employee of Pfizer, and owns stock\/options in Pfizer. Robert J Fountaine is an employee of Pfizer and owns stock\/options in Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki, Good Clinical Practice, Good Laboratory Practice, International Conference on Harmonization guidelines, and all applicable local regulations. Independent ethics committees\/institutional review boards at each study center approved the protocol. Participants provided written informed consent before starting the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}